The page below is a sample from the LabCE course Tracking Antibiotic-Resistant Tuberculosis. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Tracking Antibiotic-Resistant Tuberculosis (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 94 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

TB Wonder Drugs

Not until the 1943 discovery of the antibiotic streptomycin was isolated from the soil fungus Streptomyces griseus was there any hope of eradicating the devastating disease caused by M. tuberculosis. Yet, after a few months of this treatment, patients often regressed, as the organism selected for resistance to the antibiotic. Improvement was noted, however, when patients were administered para-aminosaliclic acid (PAS) combined with the streptomycin. Then in 1953, the revolutionary discovery of isoniazid introduced the global “wonder drug” for TB patients. As sanatorium treatment declined, the advent of antibiotic therapy proclaimed the beginning of the disappearance of the disease. By 1960, many sanatoria had closed and the combined antibiotic therapy of streptomycin, PAS, and isoniazid (given daily for a year) was declared a 100% success. Rifamycin (a rifampin derivative) was followed by pyrazinamide, ethambutol, cycloserine, and ethionamide, among the antibiotics that served as “second-line” treatment.
Although the fear of transmission to other patients and staff members continued, hospitals were now able to care for patients formerly sent for sanatorium care. No longer separated for months or years from their homes and families, they benefited from a shorter recovery period.